BioCardia, Inc. (NASDAQ:BCDA) Short Interest Down 19.5% in December

BioCardia, Inc. (NASDAQ:BCDA) was the target of a significant decline in short interest in December. As of December 15th, there was short interest totalling 83,400 shares, a decline of 19.5% from the November 30th total of 103,600 shares. Based on an average daily volume of 55,000 shares, the short-interest ratio is currently 1.5 days. Currently, 2.2% of the shares of the stock are short sold.

BioCardia Price Performance

BCDA traded up $0.03 during trading hours on Tuesday, reaching $2.18. The company’s stock had a trading volume of 55,586 shares, compared to its average volume of 267,163. The stock has a market cap of $9.99 million, a PE ratio of -0.52 and a beta of 1.25. BioCardia has a fifty-two week low of $1.63 and a fifty-two week high of $10.79. The business’s 50-day moving average is $2.23 and its 200-day moving average is $2.65.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of BioCardia in a research report on Wednesday, December 18th.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.